BusinessCRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer TherapiesBy Nasdaq OMXAug 22, 2017, 11:30 AM UTC
BusinessTeneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell TherapyBy Nasdaq OMXMay 22, 2017, 12:02 PM UTC
BusinessTeneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell TherapyBy Nasdaq OMXMay 22, 2017, 12:02 PM UTC
BusinessTeneobio’s Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine ReleaseBy Nasdaq OMXMay 1, 2017, 12:01 PM UTC
